An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

[print friendlyprint friendly]

Recent postings to
Worst Pills, Best Pills Newsletter Articles

  View the entire October 2014 issue in PDF format

  • Benzocaine Teething Gels Associated With Life-Threatening Condition
    (October 2014)
    Learn why benzocaine-containing gels and liquids should never be used to treat teething discomfort and about the actions Public Citizen’s Health Research Group has taken to end the use of these dangerous products in infants.
  • Generic Drugs: Don’t Let Appearances Fool You
    (October 2014)
    Stopping beneficial medications threatens patient health. In his monthly editor’s column, Dr. Michael Carome discusses an intriguing new study showing that patients are more likely to stop taking important medications when pharmacies substitute one generic version of a drug for another differing in shape or color.
  • Widely Used Prostate Cancer Treatment Not Beneficial for Most
    (October 2014)
    Many men with localized prostate cancer are being treated unnecessarily with a commonly used class of drugs. Find out which drugs are being overused.
  • Eszopiclone (LUNESTA): Too Dangerous at Any Dose
    (October 2014)
    The Food and Drug Administration’s recent recommendation to lower the starting dose of the insomnia drug eszopiclone is insufficient to address the drug’s dangers. Learn why Public Citizen’s Health Research Group continues to designate eszopiclone as Do Not Use.
  • Severe Allergic Reactions to Acne Treatments
    (October 2014)
    Many commonly used over-the-counter acne products pose a risk of serious allergic reactions in children and adults. This article provides information on how to minimize the risk when starting treatment with one of these products.

  View the entire September 2014 issue in PDF format

  • New Diabetes Drug Dapagliflozin (FARXIGA): Risks Outweigh Benefits
    (September 2014)
    Learn about the many dangers of one of the newest diabetes drugs approved in the U.S., dapagliflozin, which has been designated as Do Not Use by Public Citizen’s Health Research Group.
  • A Dangerous Gap in FDA Recall Authority
    (September 2014)
    The recent refusal of two companies to immediately recall potentially contaminated sterile drugs when requested to do so by the Food and Drug Administration highlights a serious gap in the agency’s regulatory authority. Learn more about the companies involved and the action that must be taken by Congress to address the public health threat posed by such industry obstinacy.
  • New Blood Pressure Treatment Guidelines Released
    (September 2014)
    In December 2013, new guidelines for treatment of high blood pressure were issued by a group of experts appointed by the National Institutes of Health. The guidelines stirred much controversy in the medical community. Get the Public Citizen Health Research Group’s independent take on these new guidelines.
  • Should You Take Aspirin to Prevent Pancreatic Cancer?
    (September 2014)
    Perhaps you have seen some of the recent newspaper coverage of a National Cancer Institute-funded study suggesting that long-term aspirin use may be associated with a decreased risk of pancreatic cancer. In this article, Public Citizen’s Health Research Group reviews the study, compares it with earlier evidence and offers our recommendations.
  • A Brief Guide to Understanding Medical Studies
    (September 2014)
    News stories often excitedly report about the results of the latest medical study. Learn about the three main types of medical studies and find out which type provides the most reliable information for assessing the risks and benefits of drugs and other medical treatments.

  View the entire August 2014 issue in PDF format

  • New Atrial Fibrillation Treatment Guidelines Released
    (August 2014)
    Atrial fibrillation is one of the most common heart rhythm disorders, afflicting more than 2.7 million Americans. Learn about the most recent guidelines for treating this disorder, issued by the American College of Cardiology and the American Heart Association, and about Public Citizen’s Health Research Group’s assessment of those guidelines.
  • FDA’s Recent Action on Testosterone Products: Grossly Insufficient
    (August 2014)
    The FDA recently required manufacturers of all approved testosterone products to include a general warning on the product labeling about the risk of developing blood clots in veins. Find out why the new warning is dangerously incomplete.
  • Human Growth Hormone, ‘the Sweet Syringe of Youth’: Myths, Evidence and Controversy
    (August 2014)
    Numerous advertisements in magazines and on television and the Internet tout the miraculous age-reversing and bodybuilding properties of synthetic growth hormone treatment. This article critically reviews the evidence surrounding these health claims.
  • Type 2 Diabetes Drug Alogliptin Causes Liver Toxicity
    (August 2014)
    Learn why Public Citizen’s Health Research Group has designated the following three new Type 2 diabetes drugs as Do Not Use: alogliptin (NESINA), the combination of alogliptin and metformin (KAZANO), and the combination of alogliptin and pioglitazone (OSENI).

   View back issues January 2004 - present

Additional Information from Public Citizen
Copyright © 2014 Public Citizen's Health Research Group. All rights reserved.